SCHEMBL2299162

SCHEMBL2299162

FC(F)(F)Oc1cccc(COC2CC[N]CC2)c1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CARM1 Q86X55 5/20 0.56
PRMT6 Q96LA8 5/20 0.56
SIGMAR1 Q99720 2/20 0.48
DRD4 P21917 1/20 0.48
SLC6A4 P31645 1/20 0.45
SCN9A Q15858 1/20 0.44
TACR1 P25103 1/20 0.42
ALOX5AP P20292 1/20 0.41
FEN1 P39748 1/20 0.41
EPHX1 P07099 1/20 0.41
CETP P11597 1/20 0.40
OPRM1 P35372 1/20 0.40
CHRM2 P08172 1/20 0.40
CHRM1 P11229 1/20 0.40
CHRM3 P20309 1/20 0.40
KCNN4 O15554 1/20 0.39
HCRTR1 O43613 1/20 0.39
HCRTR2 O43614 1/20 0.39
KDM5A P29375 1/20 0.39
KDM4C Q9H3R0 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2300096 0.84 SLC6A4 (0.57) CARM1PRMT6SIGMAR1DRD4SLC6A4
SCHEMBL2299165 0.83 CARM1 (0.56) CARM1PRMT6SLC6A4SCN9ACHRM1
SCHEMBL31071605 0.82 SLC6A4 (0.62) CARM1PRMT6SIGMAR1DRD4SLC6A4
SCHEMBL2297042 0.81 CARM1 (0.58) CARM1PRMT6SIGMAR1DRD4TACR1
SCHEMBL2296998 0.79 MGLL (0.44) CARM1PRMT6SLC6A4SCN9A
SCHEMBL3126964 0.79 CARM1 (0.55) CARM1PRMT6SIGMAR1DRD4SLC6A4
SCHEMBL3121802 0.77 NAAA (0.42) CARM1PRMT6SIGMAR1DRD4HCRTR1
SCHEMBL27665952 0.77 CHRM2 (0.54) CARM1PRMT6SIGMAR1DRD4SLC6A4
SCHEMBL3114317 0.76 CARM1 (0.55) CARM1PRMT6SLC6A4TACR1MAOB
SCHEMBL3118807 0.76 IDO1 (0.49) CARM1PRMT6SLC6A4TACR1OPRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9334269-B2 Carboxamides as inhibitors of voltage-gated sodium channels AMGEN INC. (US) 2016-05-10 US disclosed
US-20130131035-A1 CARBOXAMIDES AS INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS AMGEN INC. (US) 2013-05-23 US disclosed
EP-2536689-A1 ARYL CARBOXAMIDE DERIVATIVES AS SODIUM CHANNEL INHIBITORS FOR TREATMENT OF PAIN Amgen Inc. (US) 2012-12-26 EP disclosed
WO-2011103196-A1 ARYL CARBOXAMIDE DERIVATIVES AS SODIUM CHANNEL INHIBITORS FOR TREATMENT OF PAIN AMGEN INC. (US) 2011-08-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130131035-A1 CARBOXAMIDES AS INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS CACNA1B, SCN1A, CACNA1I CARM1 3558/4885PRMT6 3503/4885SIGMAR1 618/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.